Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor
MWN-AI** Summary
Adagene Inc. has appointed Dr. Axel Hoos, a prominent figure in immuno-oncology, as Executive Advisor to its leadership team. Dr. Hoos has a distinguished background, notable for coining the term "immuno-oncology" and leading the development of YERVOY® (Ipilimumab), the first FDA-approved immune checkpoint inhibitor. His arrival comes at a crucial time as Adagene progresses in clinical development, particularly with its innovative anti-CTLA-4 therapies designed to improve safety and efficacy in cancer treatment.
Adagene is at the forefront of discovering and developing antibody-based therapies, focusing on optimizing CTLA-4 targeting, a critical player in T-cell regulation. Their lead candidate, ADG126, employs a unique masking technology to engage CTLA-4 specifically in the tumor microenvironment, potentially enhancing its effectiveness against hard-to-treat cancer types, such as Metastatic Microsatellite-stable Colorectal Cancer (MSS CRC).
Under CEO Peter Luo's vision, Dr. Hoos's expertise is expected to guide the strategic clinical development of these therapies, leveraging Adagene’s proprietary SAFEbody™ technology, which aims to mitigate the adverse effects typically linked with antibody treatments. This technology allows for tumor-specific targeting while preserving healthy tissue, which represents a significant advancement in the field of cancer immunotherapy.
Dr. Hoos's previous roles, including CEO of Scorpion Therapeutics and senior positions at GSK and Bristol-Myers Squibb, exemplify his capacity to drive innovative oncology solutions. Together, Adagene and Dr. Hoos aim to redefine existing paradigms in immunotherapy, potentially expanding treatment options for previously underserved patient populations. As the company continues to develop its promising pipeline, Dr. Hoos's leadership will be pivotal in navigating this complex landscape.
MWN-AI** Analysis
Adagene Inc. (Nasdaq: ADAG) has recently made headlines with the strategic appointment of Dr. Axel Hoos as Executive Advisor. Dr. Hoos brings a wealth of experience in immuno-oncology, specifically his pioneering work leading to the development of YERVOY® (Ipilimumab), the first FDA-approved immune checkpoint inhibitor. His expertise is particularly valuable as Adagene advances its innovative pipeline of antibody therapies centered around CTLA-4, a challenging but promising target in cancer immunotherapy.
Investors should view this appointment as a positive signal for Adagene’s trajectory. The introduction of ADG116 and ADG126 showcases a sophisticated approach to circumvent the narrow therapeutic window associated with CTLA-4 by employing precision masking technology, potentially enhancing efficacy while reducing toxicity. This is crucial for expanding treatment options into difficult-to-treat patient populations, such as those with cold tumors like MSS colorectal cancer, where traditional immunotherapies have limited success.
Given the complexity of developing safe, effective immunotherapies, the presence of a seasoned expert like Dr. Hoos could accelerate developmental timelines and improve clinical outcomes. Furthermore, with his background in leading successful oncology initiatives at firms like GSK and Bristol-Myers Squibb, his guidance may streamline Adagene’s strategy and execution in clinical trials.
Market sentiment towards biotech firms, particularly those in immuno-oncology, can be volatile; however, momentum may shift favorably with favorable clinical results and strategic advancements. Investors should monitor the progress of ADG126 and pay close attention to upcoming trial data releases, as success could significantly elevate Adagene’s market position.
In conclusion, Adagene’s innovative approach combined with the leadership of Dr. Hoos could redefine its operational landscape, presenting a compelling investment opportunity in the evolving field of cancer immunotherapy.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
SAN DIEGO and SUZHOU, China, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Dr. Axel Hoos as Executive Advisor.
“Adagene is advancing the field of Immuno-Oncology with its pipeline of innovative antibodies centered around CTLA-4, a master-regulator of T-cell responses. This includes ADG116 to differentially engage CTLA-4 for greater T-reg depletion, and ADG126 to mask the CTLA-4 binder (ADG116) until it reaches the tumor microenvironment aiming for an enhanced efficacy and reduced toxicity profile. The design of these antibodies may allow a broader utility of CTLA-4 targeting in cancer immunotherapy” said Dr. Hoos. “CTLA-4 is a proven but notoriously difficult target. Most next-generation programs have not been able to overcome the narrow therapeutic window thus requiring novel designs. With Adagene’s programs the benefit/risk ratio of CTLA-4 targeting may favorably shift and allow treatment of new populations such as cold tumors like MSS CRC, where current immunotherapies have little to no effect.”
“Dr. Hoos is an icon in immuno-oncology—both as the creator of the term and a driving force behind the clinical development of YERVOY ® (Ipilimumab), the first FDA-approved immune checkpoint inhibitor,” said Peter Luo, CEO of Adagene. “We’re honored to welcome him to our outstanding team of Executive Advisors. His leadership comes at a pivotal moment, as we advance ADG126 through a key turning point in clinical development and continue to expand our SAFEbody™ pipeline powered by our innovative masking technology platform. We look forward to his invaluable guidance in clinical development of anti-CTLA-4 therapy as we work to redefine the future of precision immunotherapy.”
From 2021 to 2024 Dr. Axel Hoos served as CEO of Scorpion Therapeutics, which was acquired by Eli Lilly in 2025 for up to $2.5 billion. Previously, Dr. Hoos was the SVP and Head of the Oncology Therapeutic Area at GSK, where he oversaw the rebuilding of GSK’s Oncology business after its divestiture to Novartis in 2015.
Prior to GSK, Dr. Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS) where he and his team developed YERVOY ® (Ipilimumab), the first immune checkpoint inhibitor drug, and created the term Immuno-Oncology to characterize the interplay of the immune system and cancer in immunotherapy drug development.
Dr. Hoos received his M.D. in Medicine from Heidelberg University, and his Ph.D. in Molecular Oncology from the German Cancer Research Center (DKFZ). He trained in general surgery at the Technical University of Munich and as a fellow in cancer research at Memorial Sloan-Kettering Cancer Center and is an alumnus of the Program for Leadership Development at Harvard Business School.
About Adagene
Adagene Inc. (Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody precision masking technology in multiple approaches at the vanguard of science.
Powered by its proprietary Dynamic Precision Library (DPL) platform, composed of NEObody™, SAFEbody ® , and POWERbody™ technologies, Adagene’s highly differentiated pipeline features novel immunotherapy programs. The company’s SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the tumor microenvironment, this allows for tumor-specific targeting of antibodies, while minimizing on-target off-tumor toxicity in healthy tissues.
Adagene’s lead clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody that targets a unique epitope of CTLA-4 in regulatory T cells (Tregs) in the tumor microenvironment. ADG126 is currently in phase 1b/2 clinical studies in combination with anti-PD-1 therapy, particularly focused on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). Validated by ongoing clinical research, the SAFEbody platform can be applied to a wide variety of antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multispecific T-cell engagers.
For more information, please visit: https://investor.adagene.com.
Follow Adagene on WeChat, LinkedIn and X.
SAFEbody ® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.
Investor Contacts:
Raymond Tam
raymond_tam@adagene.com
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
FAQ**
How does Adagene Inc. (ADAG) plan to leverage its SAFEbody technology to enhance immunotherapy options for patients in San Diego and Suzhou by addressing the unique healthcare needs and local cancer prevalence rates?
With the appointment of Dr. Axel Hoos, what role will he play in advancing Adagene Inc. (ADAG)'s clinical programs, particularly in relation to the cancer research initiatives in San Diego and Suzhou?
Given the advancements in precision immunotherapy by Adagene Inc. (ADAG), what are the potential implications for cancer treatment accessibility and research collaboration between San Diego and Suzhou?
In what ways can Adagene Inc. (ADAG) benefit from the biotechnology ecosystems in both San Diego and Suzhou, particularly in terms of partnerships, talent acquisition, and market expansion?
**MWN-AI FAQ is based on asking OpenAI questions about Adagene Inc. (NASDAQ: ADAG).
NASDAQ: ADAG
ADAG Trading
11.15% G/L:
$3.29 Last:
11,385 Volume:
$3.025 Open:
